TERN (Terns Pharmaceuticals) חוב לטווח קצר להון

Terns Pharmaceuticals (TERN) develops affordable small molecules to combat obesity and liver pathologies. The business currently relies on the clinical trial stage, which entails active cash burn in the absence of stable profits. As reflected in the pakistan chart, the asset value is 0.00, while a diversified portfolio of promising drugs significantly minimizes investment risks.

An analysis of the capital structure allows for the separation of Terns Pharmaceuticals (TERN) fundamental stability from price volatility. This indicator compares liabilities maturing within one year against equity, identifying the risk of cash flow gaps and the overall debt load. The trend of short-term loans relative to equity confirms the company's financial solvency, ensuring the resources necessary for the development of oral medications in the growing metabolic disease treatment segment.